Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: Placebo; Drug: AZD9056

Study type: Interventional

Funder types: Industry

Identifiers

NCT00700986

EUDRACT No. 2008-000752-27

D1520C00020

Details and patient eligibility

About

The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina

Enrollment: 12 estimated patients

Sex: Male

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Volunteers must be able to undergo the Electroretinography assessments
• Volunteers must have an intra ocular pressure of less than 25mmHg and 6/6 vision

Exclusion criteria

• Volunteers must pass a test that assesses whether they are at risk of narrow angle glaucoma
• Volunteers must not a family history of colour blindness, they must also pass a colour blindness test
• Volunteers must not have a history or current neurological or opthalmological (eye) disease

Trial design

12 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD9056

2

Placebo Comparator group

Treatment:

Drug: Placebo